Wobble Genomics’ technology demonstrates potential in accelerating precision medicine innovations

Wobble Genomics, a healthcare and biotechnology company at the forefront of long-read RNA sequencing, will present new data this week at the San Antonio Breast Cancer Symposium (SABCS) that demonstrates the ability of its technology platform to provide deep biological insights critical for drug discovery and development¹, building on previous data which established the technology’s strong predictive performance as a diagnostic tool².

Within its prospective study, Wobble Genomics’ technology has uncovered hundreds of thousands of novel full-length RNA isoforms, many of which are cancer-specific and include previously uncharacterized variants of oncogenes and tumor suppressors¹.

By enhancing the representation of important genes and transcripts that drive disease progression, Wobble’s technology shows promise as a tool for the discovery of new therapeutic targets, which could help enable the development of highly targeted cancer treatments such as mRNA cancer vaccines and antibody-drug conjugates (ADCs)¹.

The novel full-length RNA isoforms have been captured within the company’s comprehensive database, containing therapeutically relevant targets for cancer treatments with over 35,000 cancer-specific RNA isoforms from its studies, which can enable the development of tailored treatments like RNA-based cancer vaccines and ADCs¹.

These population-level targets are particularly significant because they represent shared tumor-specific properties across patients, making them ideal candidates for broadly applicable yet highly specific therapies. The unique protein-coding regions encoded by these isoforms can also serve as neoantigen targets for personalized immunotherapies, enabling RNA cancer vaccines or ADCs to precisely target cancer cells, while minimizing harm to healthy tissue.

Wobble Genomics’ platform has also demonstrated the ability to provide a comprehensive view of the patient’s immune system, which supports the potential development of immunotherapies tailored to specific immune profiles and enables patient stratification to optimize treatment responses¹. The identification of unique transcripts and novel cancer-specific targets further enhances the platform’s potential to advance precision oncology, by linking immune dynamics with tumor biology for highly targeted therapies.

References

1. Kuo, R. I et al. Novel Liquid Biopsy Technology Reveals Cancer-Specific Isoforms for Breast Cancer Diagnosis and Therapy, San Antonio, December 2024.
2. Kuo, R. I et al. Novel Liquid biopsy technology reveals hidden RNA signals in early-stage breast cancer. Poster presented at the Early Detection of Cancer Conference, San Francisco, October 2024.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>